Humonix Biosciences Names Founder Karen Torrejon As CEO To Drive Expansion

Humonix Biosciences, Inc., a pioneering specialty pharmaceutical research firm, has recently announced a significant leadership change with Dr. Karen Torrejon taking the helm as the new Chief Executive Officer. Dr. Torrejon, the visionary behind Humonix's inception in 2014, returns to steer the company through an expansive phase, broadening its scientific platform to offer enhanced research capabilities to its pharmaceutical and biotechnology clients.

At the core of Humonix's innovative approach is its proprietary 3D human tissue-based system. Initially developed under the Glauconix brand for glaucoma studies, this technology has evolved to cover a wider spectrum of diseases, including retinal vascular disease, pulmonary fibrosis, and renal fibrosis. This advancement underscores Humonix's commitment to refining the drug development process by facilitating the transition from preclinical research to human efficacy predictions. The company's validated human tissue models are instrumental in streamlining drug development, reducing costs, and increasing the likelihood of program success.

Dr. Torrejon expressed enthusiasm about her return to leadership, emphasizing the company's unique position in testing compounds using human tissues ex vivo. This capability is crucial for selecting promising candidates for further development early in the research process. "Our ability to test compounds in human tissues ex vivo sets us apart," Dr. Torrejon stated, highlighting the strategic advantage Humonix offers to its partners.

The Board of Humonix has also extended its gratitude to Ms. Southern for her significant contributions to the company's growth in the contract research space. Richard Frederick, Chairman of the Humonix Board, and Barbara Wirostko, MD, FARVO, a board member and Chief Medical Officer of Qlaris Bio, Inc., both praised Dr. Torrejon's scientific expertise and leadership qualities. They anticipate that under her guidance, Humonix will venture into new research domains, creating substantial value for industry partners and patients alike.

Founded in Albany, New York, Humonix Biosciences aims to revolutionize preclinical drug and biologic efficacy prediction with its 3D human tissue models. By minimizing reliance on animal testing, the company aligns with modern ethical standards and regulatory expectations, including those outlined in the FDA’s Modernization Act 2.0. Humonix's innovative approach has attracted investments from Excell Partners, Eastern New York Angels, and various private equity investors.

For further information about Humonix Biosciences and its cutting-edge research capabilities, interested parties are encouraged to visit www.humonixbio.com or contact George Torrejon at [email protected] or (631) 487-5553.